It's good to see AVH branching out to other niche areas, that is a good move on their part, because the cost of re cell is allowing other entrants into the epi dermis field, the competition is coming in thick and fast, there will be a better and cheaper alternative to re cell soon, it's a shame in some ways at the product itself seems to work well, it is basically the cost of the product that will cause it's own demise in the burns and surgical wound area.
Ann: AVITA Receives FDA IDE Approval to Evaluate RECELL for Vitil, page-7
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.00 |
Change
0.030(1.01%) |
Mkt cap ! $204.2M | |||
| Open | High | Low | Value | Volume |
| $2.97 | $3.04 | $2.97 | $470.6K | 156.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3500 | $2.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.00 | 920 | 4 |
View Market Depth
| Last trade - 10.38am 31/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |